Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease

Rituximab maintenance therapy should be considered for patients with relapsing pancreaticobiliary IgG4-RD who receive induction rituximab treatment. Younger age, persistent disease activity after induction therapy, and increased serum concentrations of alkaline phosphatase either before or after induction therapy, associate with increased risk of relapse. These factors should be considered in deciding whether or not to provide maintenance rituximab therapy.

http://ift.tt/2HkNbKR